A conceptual framework for assessing the public health effects from snus and novel non-combustible nicotine products.

e-cigarettes nicotine preventive work public health snus tobacco

Journal

Nordisk alkohol- & narkotikatidskrift : NAT
ISSN: 1458-6126
Titre abrégé: Nordisk Alkohol Nark
Pays: United States
ID NLM: 100937320

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 27 10 2020
accepted: 12 05 2021
entrez: 21 3 2022
pubmed: 22 3 2022
medline: 22 3 2022
Statut: ppublish

Résumé

The tobacco industry plans to base their future earnings on the production of non-combustible nicotine products. These might replace or come in addition to the more harmful cigarettes that historically have dominated the nicotine market in the Nordic countries. The authorities in each country must decide whether the products should have market access and, in that case, how strictly they should be regulated. Our aim is to present a framework that can assist the health authorities to make a regulation where benefits will outweigh the harms. In a public health perspective, health gains from substitution must be weighed against the health loss from additional use. The main elements of the weighing will be based on the information about the absolute risk of the products, their relative risk compared to conventional cigarettes and how the users are composed according to smoking status. We apply the framework on snus as used in Norway - a product with an established usage pattern and epidemiologically assessed health risks. The framework consists of (i) a comprehensive set of specific user patterns that may result in health deterioration and user patterns that may result in health benefits, (ii) an estimation of the number of people with health-augmenting and health-impairing user patterns, respectively, and (iii) an estimation of the degree of health deterioration or health benefit that will affect the persons with the different user patterns. The net effect on public health will appear as an overall result of the number of people with positive and negative user patterns, respectively, in combination with the magnitude of the change in health status these people will experience. The use of an explicit framework highlights how a political decision may affect nicotine use and health-related outcomes. The framework breaks open a large and complex question into smaller pieces and requires the authorities to expose and explain the kind of evidence and reasoning behind regulations of novel nicotine products.

Identifiants

pubmed: 35309855
doi: 10.1177/14550725211021248
pii: 10.1177_14550725211021248
pmc: PMC8900171
doi:

Types de publication

Journal Article

Langues

eng

Pagination

586-604

Informations de copyright

© The Author(s) 2021.

Déclaration de conflit d'intérêts

Declaration of conflicting interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Int J Environ Res Public Health. 2014 Nov 13;11(11):11705-17
pubmed: 25402565
Regul Toxicol Pharmacol. 2015 Jun;72(1):87-93
pubmed: 25819932
N Engl J Med. 2017 Sep 21;377(12):1111-1114
pubmed: 28813211
Int J Environ Res Public Health. 2015 May 21;12(5):5439-64
pubmed: 26006122
Tob Control. 2005 Dec;14(6):422-4
pubmed: 16319367
Addiction. 2021 Jul;116(7):1848-1858
pubmed: 33394529
Addiction. 2018 Oct;113(10):1776-1783
pubmed: 28786147
Nicotine Tob Res. 2017 Feb;19(2):149-159
pubmed: 27613952
Regul Toxicol Pharmacol. 2017 Jun;86:265-278
pubmed: 28342844
Tob Control. 2001 Sep;10(3):201-3
pubmed: 11544374
Epidemiology. 2016 Nov;27(6):819-26
pubmed: 27093020
Lancet. 2017 Oct 14;390(10104):1722-1724
pubmed: 29047432
Nicotine Tob Res. 2019 Jan 1;21(1):41-47
pubmed: 29617887
Addict Res Theory. 2012 Dec;20(6):447-455
pubmed: 23204990
Drug Alcohol Depend. 2017 May 1;174:209-214
pubmed: 29350617
Eur Addict Res. 2014;20(5):218-25
pubmed: 24714502
PLoS One. 2015 Mar 27;10(3):e0121008
pubmed: 25815840
Harm Reduct J. 2019 Apr 11;16(1):27
pubmed: 30975137
Addiction. 2020 Jan;115(1):170-174
pubmed: 31502348
Addiction. 2011 Jan;106(1):162-7
pubmed: 20883459
BMC Public Health. 2014 Dec 17;14:1296
pubmed: 25518992
Harm Reduct J. 2019 Aug 20;16(1):50
pubmed: 31429765
Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2035-42
pubmed: 15598758
Tob Control. 2013 Nov;22(6):382-8
pubmed: 22634571
Regul Toxicol Pharmacol. 2013 Jun;66(1):1-5
pubmed: 23454227
Tob Control. 2006 Jun;15(3):210-4
pubmed: 16728752
PLoS One. 2018 Mar 14;13(3):e0193328
pubmed: 29538396
Nicotine Tob Res. 2014 Jun;16(6):815-9
pubmed: 24500685
Drug Alcohol Depend. 2012 Jun;123 Suppl 1:S3-17
pubmed: 22261179
Lancet. 2007 Jun 16;369(9578):2010-2014
pubmed: 17498798
Tidsskr Nor Laegeforen. 2016 Apr 05;136(6):544-6
pubmed: 27052915
Addiction. 2017 Jan;112(1):8-17
pubmed: 27109256
Tob Control. 2005 Oct;14(5):315-20
pubmed: 16183982
Int J Environ Res Public Health. 2016 Nov 09;13(11):
pubmed: 27834883
BMC Public Health. 2019 Sep 13;19(1):1265
pubmed: 31519157
Regul Toxicol Pharmacol. 2017 Aug;88:192-213
pubmed: 28651854
Inhal Toxicol. 2005 Dec 1;17(13):741-8
pubmed: 16195209
JAMA Intern Med. 2015 Oct;175(10):1671-80
pubmed: 26322924
Nicotine Tob Res. 2008 Feb;10(2):315-23
pubmed: 18236296
Nicotine Tob Res. 2020 Jun 12;22(7):1123-1130
pubmed: 31680169
Addiction. 2017 Feb;112(2):340-348
pubmed: 27741374

Auteurs

Karl Erik Lund (KE)

Norwegian Institute of Public Health, Oslo, Norway.

Tord Finne Vedøy (TF)

Norwegian Institute of Public Health, Oslo, Norway.

Classifications MeSH